OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 561 - 570 of 796 studies

Cancer and neoplasms

A PHASE II, RANDOMIZED, OPEN-LABEL STUDY EVALUATING TWO INAVOLISIB DOSE LEVELS IN COMBINATION WITH FULVESTRANT IN PARTICIPANTS WITH PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO46063 (optINAVO))

Investigation of White Blood Cells to support the Development of Engineered Regulatory T Cell Therapies

Inflammatory and immune system

Platform Open-label Interventional Biomarker Study of Targeted Therapies for the Treatment of Adult Subjects with Rheumatoid Arthritis. (M26-033)

Oral and Gastrointestinal

Trial to Evaluate Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib in Participants With Moderately-to-Severely Active Crohn’s Disease (ZODIAC)

Oral and Gastrointestinal

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes) (N1T-MC-MALO (SYNERGY-Outcomes))

Neurological

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects with Huntington’s Disease (INSIGHTT)

Blood

A MULTICENTER, RANDOMIZED, OPEN‑LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS (ZEBRHA-1)

Biopsy Investigation of Oxford Synovitis Cohort

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome. (FORWARD)

Natural history and standards of care in Duchenne Muscular Dystrophy - The U.K. NorthStar Clinical Network.